Glaukos Corporation $GKOS Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC lessened its holdings in shares of Glaukos Corporation (NYSE:GKOS) by 12.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 43,615 shares of the medical instruments supplier’s stock after selling 6,480 shares during the quarter. Intech Investment Management LLC’s holdings in Glaukos were worth $4,925,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Harbour Investments Inc. acquired a new position in Glaukos during the 4th quarter worth $86,000. New Age Alpha Advisors LLC raised its stake in shares of Glaukos by 73.8% in the 4th quarter. New Age Alpha Advisors LLC now owns 4,309 shares of the medical instruments supplier’s stock worth $487,000 after buying an additional 1,829 shares in the last quarter. William Blair Investment Management LLC raised its stake in shares of Glaukos by 1.2% in the 4th quarter. William Blair Investment Management LLC now owns 1,106,918 shares of the medical instruments supplier’s stock worth $124,982,000 after buying an additional 13,174 shares in the last quarter. Lisanti Capital Growth LLC bought a new stake in shares of Glaukos in the 4th quarter worth $2,725,000. Finally, Legato Capital Management LLC bought a new stake in shares of Glaukos in the 4th quarter worth $756,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on GKOS shares. Stifel Nicolaus set a $170.00 price objective on Glaukos in a research note on Thursday, April 30th. Citigroup boosted their price objective on Glaukos from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. William Blair reissued an “outperform” rating on shares of Glaukos in a research note on Tuesday, May 26th. JPMorgan Chase & Co. boosted their price objective on Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a research note on Tuesday, April 21st. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $146.17.

Glaukos Stock Down 0.3%

Shares of Glaukos stock opened at $103.08 on Monday. The stock’s fifty day moving average is $121.31 and its 200-day moving average is $114.45. The firm has a market capitalization of $6.05 billion, a PE ratio of -31.43 and a beta of 0.83. The company has a quick ratio of 4.73, a current ratio of 5.43 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $148.11.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.12. The company had revenue of $150.57 million for the quarter, compared to analyst estimates of $137.00 million. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.Glaukos’s revenue for the quarter was up 41.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.22) earnings per share. Equities analysts anticipate that Glaukos Corporation will post -0.57 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Alex R. Thurman sold 10,000 shares of the business’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $140.00, for a total transaction of $1,400,000.00. Following the sale, the chief financial officer directly owned 43,681 shares of the company’s stock, valued at $6,115,340. The trade was a 18.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joseph E. Gilliam sold 19,573 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $143.54, for a total value of $2,809,508.42. Following the sale, the chief operating officer directly owned 73,419 shares in the company, valued at $10,538,563.26. This trade represents a 21.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 45,930 shares of company stock valued at $6,321,363 over the last ninety days. 5.90% of the stock is currently owned by company insiders.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.